瑞泰新材(301238.SZ):與挪威一家公司簽訂的框架供貨協議,預測採購數量對客户不構成強制約束力,已開始小批量供貨
格隆匯6月29日丨有投資者向瑞泰新材(301238.SZ)提問,“2022年貴公司公吿,瑞泰新材子公司華榮化工與挪威一家公司簽訂了框架供貨協議。合約是2023年開始供貨。請公司開始履行合約了嗎?每月發貨量是多少?如果沒有履行合約,如果取消了合同,是不是當時的業務人員有問題。是不是也要發佈公吿!”
瑞泰新材回覆稱,該協議屬於框架性約定,協議中預測採購數量對客户不構成強制約束力,客户實際採購金額存在不確定性,敬請廣大投資者注意投資風險。公司已開始小批量供貨,並將根據監管部門相關規定履行相應的披露義務,敬請關注公司定期報吿或相關公吿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.